To Evaluate the Bioavailability of a Tablet of AZD1656

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

11 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-12-31

Study Completion Date

2009-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate the bioavailability of a tablet of AZD1656.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Relative Bioavailability Study Measuring the Extent and Rate of Absorption of Different Tablet Formulations of AZD1656 in Type 2 Diabetes Mellitus (T2DM) Patients

NCT01221519

Type 2 Diabetes Mellitus High Blood Sugar

COMPLETED PHASE1

Study to Assess the Safety and Tolerability After Multiple Oral Doses of AZD1656 in Patients With Type 2 Diabetes Mellitus Treated With Metformin

NCT00817778

Type 2 Diabetes

COMPLETED PHASE2

Safety and Tolerability After Four Weeks of Treatment With AZD1656 in Patients With Type 2 Diabetes

NCT00856908

Type II Diabetes

COMPLETED PHASE2

To Assess Safety, Tolerability, Pharmacokinetics/Pharmacodynamics and the Effect of Fasting After Single Oral Doses of AZD5658 in Type 2 Diabetes

NCT01176097

Type 2 Diabetes

COMPLETED PHASE1

To Evaluate Safety and Tolerability After Multiple Oral Doses of AZD1656 in Type 2 Diabetes Patients on Top of Insulin

NCT00768105

Type 2 Diabetes

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 1 Diabetes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

AZD1656 tablet + food

Group Type ACTIVE_COMPARATOR

AZD1656

Intervention Type DRUG

Single dose oral tablet

AZD1656

Intervention Type DRUG

Single dose oral suspension

2

AZD1656 susp. without food

Group Type ACTIVE_COMPARATOR

AZD1656

Intervention Type DRUG

Single dose oral tablet

AZD1656

Intervention Type DRUG

Single dose oral suspension

3

AZD1656 tablet

Group Type ACTIVE_COMPARATOR

AZD1656

Intervention Type DRUG

Single dose oral tablet

AZD1656

Intervention Type DRUG

Single dose oral suspension

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AZD1656

Single dose oral tablet

Intervention Type DRUG

AZD1656

Single dose oral suspension

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female, type I diabetes patients, female with non child-bearing potential.
* Treated with insulin for more than 3 years. Well controlled HbA1c.
* Have a body mass index (BMI) ≥19 and ≤35

Exclusion Criteria

* Clinically significant illness except type I diabetes, or clinically relevant trauma, as judged by the investigator, within 2 weeks before the first administration of the investigational product
* Daily use of nicotine containing substances.

Minimum Eligible Age

20 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No